New Questions Raised About ROCKET AF, Pivotal Xarelto Trial Chaired By Califf

Disturbing questions are being raised about the integrity and reliability of crucial data in the ROCKET AF trial. The investigation could have important implications on several fronts. First, the trial serves as the basis for the use of the blockbuster drug rivaroxaban (Xarelto, Johnson & Johnson) for stroke prevention in atrial fibrillation. Second, the trial...Click here to continue reading...

Source: CardioBrief - December 1, 2015 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms People, Places & Events Policy & Ethics Califf EMA FDA rivaroxaban warfarin Xarelto Source Type: blogs